These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23969422)

  • 21. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
    Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
    Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerated hippocampal atrophy rates in stable and progressive amnestic mild cognitive impairment.
    Wang PN; Liu HC; Lirng JF; Lin KN; Wu ZA
    Psychiatry Res; 2009 Mar; 171(3):221-31. PubMed ID: 19217759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progression from mild to pronounced MCI is not associated with cerebrospinal fluid biomarker deviations.
    Wallin A; Göthlin M; Gustavsson M; Zetterberg H; Eckerström C; Blennow K; Edman A; Lind K; Nordlund A; Rolstad S
    Dement Geriatr Cogn Disord; 2011; 32(3):193-7. PubMed ID: 22057225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
    de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
    J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A disease state fingerprint for evaluation of Alzheimer's disease.
    Mattila J; Koikkalainen J; Virkki A; Simonsen A; van Gils M; Waldemar G; Soininen H; Lötjönen J;
    J Alzheimers Dis; 2011; 27(1):163-76. PubMed ID: 21799247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease.
    Lueg G; Gross CC; Lohmann H; Johnen A; Kemmling A; Deppe M; Groger J; Minnerup J; Wiendl H; Meuth SG; Duning T
    Neurobiol Aging; 2015 Jan; 36(1):81-9. PubMed ID: 25277040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. White matter disease independently predicts progression from mild cognitive impairment to Alzheimer's disease in a clinic cohort.
    Prasad K; Wiryasaputra L; Ng A; Kandiah N
    Dement Geriatr Cogn Disord; 2011; 31(6):431-4. PubMed ID: 21757908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting progression to dementia in elderly subjects with mild cognitive impairment using both cognitive and neuroimaging predictors.
    Peters F; Villeneuve S; Belleville S
    J Alzheimers Dis; 2014; 38(2):307-18. PubMed ID: 23963293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer's disease.
    Julayanont P; Brousseau M; Chertkow H; Phillips N; Nasreddine ZS
    J Am Geriatr Soc; 2014 Apr; 62(4):679-84. PubMed ID: 24635004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.
    Prestia A; Caroli A; Wade SK; van der Flier WM; Ossenkoppele R; Van Berckel B; Barkhof F; Teunissen CE; Wall A; Carter SF; Schöll M; Choo IH; Nordberg A; Scheltens P; Frisoni GB
    Alzheimers Dement; 2015 Oct; 11(10):1191-201. PubMed ID: 25646957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
    J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mild cognitive impairment, risk factors and magnetic resonance volumetry: role of probable Alzheimer's disease in the family.
    Rogne S; Vangberg T; Eldevik P; Wikran G; Mathiesen EB; Schirmer H
    Dement Geriatr Cogn Disord; 2013; 36(1-2):87-98. PubMed ID: 23797189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of the PredictAD software tool to predict progression in patients with mild cognitive impairment.
    Simonsen AH; Mattila J; Hejl AM; Frederiksen KS; Herukka SK; Hallikainen M; van Gils M; Lötjönen J; Soininen H; Waldemar G
    Dement Geriatr Cogn Disord; 2012; 34(5-6):344-50. PubMed ID: 23222123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MR volumetry in mild cognitive impairment (MCI) - A useful marker to predict progression.
    Ratnavalli E
    Neurol India; 2018; 66(2):326-327. PubMed ID: 29547147
    [No Abstract]   [Full Text] [Related]  

  • 37. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
    Donohue MC; Sperling RA; Salmon DP; Rentz DM; Raman R; Thomas RG; Weiner M; Aisen PS; ; ;
    JAMA Neurol; 2014 Aug; 71(8):961-70. PubMed ID: 24886908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.
    Dickerson BC; Wolk DA;
    Front Aging Neurosci; 2013; 5():55. PubMed ID: 24130528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
    Hohman TJ; Bell SP; Jefferson AL;
    JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and multimodal biomarker correlates of ADNI neuropathological findings.
    Toledo JB; Cairns NJ; Da X; Chen K; Carter D; Fleisher A; Householder E; Ayutyanont N; Roontiva A; Bauer RJ; Eisen P; Shaw LM; Davatzikos C; Weiner MW; Reiman EM; Morris JC; Trojanowski JQ;
    Acta Neuropathol Commun; 2013 Oct; 1():65. PubMed ID: 24252435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.